Whitelab Genomics

WhiteLab Genomics is an AI-driven life sciences company founded in 2019 and backed by Y-Combinator, headquartered across Paris, Boston, and Montreal. The company stands at the convergence of artificial intelligence and biology, pioneering the accelerated development of genomic medicines. By leveraging proprietary technology and advanced computational methods, WhiteLab Genomics analyzes complex biological data to significantly accelerate and de-risk drug development, with a vision of cutting genomic medicine R&D timelines by six to seven years.

WhiteLab Genomics serves biopharmaceutical companies, academic research institutions, and gene therapy innovators seeking to optimize therapeutic candidates for safety and efficacy. Their in silico approach, bolstered by external wet lab capabilities and proprietary data, delivers industry-leading modules with agility and scalability across therapeutic areas including CNS, ophthalmology, rare diseases, oncology, neurology, and cardiac medicine.

ALFRED AI Platform

• ALFRED stands for AI-Led Framework for Rational Exploration in Drug design — WhiteLab's proprietary core technology platform.
• Combines advanced algorithms, curated databases, and cutting-edge computational biology to optimize therapeutic candidates for safety and efficacy.
• Supports diverse modalities including adeno-associated virus (AAV) vectors, lentivirus, and nanoparticles.
• Uses a guided rational approach to identify the most effective target-ligand combinations, addressing challenges across delivery methods and tissue targets.
• Multi-disciplinary platform teams develop tailored solutions to de-risk R&D advancements and achieve target product profiles.

Key Application Areas and Modules

• Target Receptors Identification and Viral Vector Design: Covers Tech R&D, In Silico Design, and Wet Lab Validation, with applications in CNS, ophthalmology, rare diseases, and oncology.
• Non-Viral Vector Design: Encompasses Tech R&D, In Silico Design, and Wet Lab Validation, targeting oncology applications including solid tumors and in vivo CAR-T cell therapies.
• Payload Design: Includes Tech R&D, In Silico Design, and Wet Lab Validation, with focus on neurology and cardiac therapeutic areas.
• The AI-driven approach empowers collaborators to achieve breakthrough solutions in genomic medicine, saving time and resources while delivering precise and effective cell and gene modalities.

AI Impact on Drug Development

• Studies show a 3.5x higher success rate of AI-assisted candidates entering Phase 1 clinical trials compared to standard approaches.
• Standard drug development success rates are below 10%, highlighting the transformative potential of WhiteLab's AI-guided methodology.
• WhiteLab's vision targets cutting genomic medicine R&D timelines by six to seven years through increased data intensity and higher candidate throughput.

Notable Partnerships and Collaborations

• Sanofi: Collaborating through the WIDGeT initiative with the TarGeT Lab at Nantes University and Institut Imagine to create novel AAV vectors with tropisms to hard-to-reach cells.
• Debiopharm: Leveraging WhiteLab's AI platform for early-stage drug R&D, de-risking assets, addressing toxicity, and developing personalized medicines.
• Cytiva: Combining Cytiva's manufacturing experience with WhiteLab's technology to help manufacturers reach clinical and regulatory milestones faster.
• Carbon Biosciences: Partnering to develop new genetic medicines by incorporating AI into capsid candidate development efforts.
• Siren Biotechnology: Accelerating universal immuno-gene therapy development for cancer and identifying new indications for AAV gene therapies.
• Institut Imagine: Participating in large-scale projects integrating AI into the development and optimization of gene therapies, with expertise in podocytopathies.
• Institut de La Vision: Collaborating on the GEAR project to improve gene therapy engineering for retinal and visual health.
• Généthon: Using WhiteLab's tools to review thousands of sequences and develop a new generation of more specific AAV vectors for neuromuscular disorders.
• INSERM: Integrating large bodies of information on critical parameters to rapidly adapt experiments and accelerate strategic genomic therapy projects.
• UMass Chan Medical School: Collaborating to accelerate the development of safer and more effective gene therapies for mitochondrial diseases and complex neurological and metabolic conditions.

Consortium Memberships and Ecosystem Involvement

• GenoTher Biocluster: WhiteLab is an industry partner advancing gene therapy innovation by integrating AI-driven capabilities with Genethon's pioneering research, addressing challenges in gene delivery, regulatory science, and manufacturing.
• NIIMBL Consortium: Member of the National Institute for Innovation in Manufacturing Biopharmaceuticals, contributing to next-generation technologies that enhance efficiency, innovation, and patient well-being in biopharmaceutical manufacturing.
• NIST Genome Editing Consortium: Collaborates with industry, academia, and government stakeholders to establish rigorous standards and measurement solutions for advancing genome editing with precision and reliability.
• TechBio France: WhiteLab Genomics organized the inaugural TechBio France 2024 national event, dedicated to the French TechBio ecosystem, in partnership with AI for Health, France Biotech, France Deeptech, and Future4Care.

WhiteLab Genomics brings together a diverse, multidisciplinary team of innovators with deep industry expertise and bold scientific vision, operating across Paris, Boston, and Montreal. Through its proprietary ALFRED AI platform and a growing network of world-class partners, the company is uniquely positioned to transform the speed, safety, and precision of genomic medicine development for patients worldwide.